Loading
A phase 2 trial of Arlocabtagene Autoleucel in multiple myeloma, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, now recruiting.
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT06297226 by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, with 230 participants planned, started 2024-03-21 and due to reach its primary completion in 2026-07-31. Interventions recorded: Arlocabtagene Autoleucel. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Arlocabtagene Autoleucel, Relapsed or refractory multiple myeloma, Bristol Myers Squibb, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.